Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) had its price target lifted by equities researchers at Stifel Nicolaus from C$17.00 to C$19.00 in a note issued to investors on Thursday, BayStreet.CA reports. Stifel Nicolaus’ price target would indicate a potential upside of 17.28% from the company’s previous close.
Other analysts also recently issued research reports about the company. Leede Financial downgraded Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 13th. Stifel Canada upgraded Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, August 12th.
Check Out Our Latest Report on Cipher Pharmaceuticals
Cipher Pharmaceuticals Price Performance
Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.15 by C$0.01. The firm had revenue of C$7.26 million for the quarter, compared to the consensus estimate of C$7.52 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Research analysts expect that Cipher Pharmaceuticals will post 1.6472868 earnings per share for the current fiscal year.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- Using the MarketBeat Dividend Yield Calculator
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- What Are the FAANG Stocks and Are They Good Investments?
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- Insider Trades May Not Tell You What You Think
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.